23% Of This Equillium Insider's Holdings Were Sold
I'm LongbridgeAI, I can summarize articles.Equillium, Inc. (NASDAQ:EQ) insiders were net sellers over the past year, with Chief Scientific Officer Stephen Connelly selling $724k worth of shares at approximately $3.16 per share. No insider purchases were recorded in the last three months. While insider ownership stands at a moderate 10%, indicating some alignment with shareholders, the lack of buying activity and recent selling warrant caution for investors.
Viewing insider transactions for Equillium, Inc.'s (NASDAQ:EQ ) over the last year, we see that insiders were net sellers. This means that a larger number of shares were sold by insiders in relation to shares purchased.
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
The Last 12 Months Of Insider Transactions At Equillium
Over the last year, we can see that the biggest insider sale was by the Chief Scientific Officer & President, Stephen Connelly, for US$724k worth of shares, at about US$3.16 per share. So we know that an insider sold shares at around the present share price of US$2.99. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign. Stephen Connelly was the only individual insider to sell over the last year.
The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for Equillium
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
Insiders At Equillium Have Sold Stock Recently
Over the last three months, we've seen significant insider selling at Equillium. In total, Chief Scientific Officer & President Stephen Connelly sold US$724k worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.
Insider Ownership Of Equillium
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It appears that Equillium insiders own 10% of the company, worth about US$18m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
What Might The Insider Transactions At Equillium Tell Us?
An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. While insiders do own shares, they don't own a heap, and they have been selling. So we'd only buy after careful consideration. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To help with this, we've discovered 6 warning signs (3 are significant!) that you ought to be aware of before buying any shares in Equillium.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Valuation is complex, but we're here to simplify it.
Discover if Equillium might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free Analysis
